Evidence map›Paper›PMID 42542447›Full record

ArticleActa neuropathologica2026

Proteomic comparison of hippocampal neurofibrillary tangles in PART, intermediate Alzheimer's disease and advanced Alzheimer's disease.

Manon Thierry, Dominique Leitner, Kaleah Balcomb, Tomas Kavanagh, Lauren Tang, Evgeny Kanshin, Christopher William, Derek Oakley, Bradley Hyman, Beatrix Ueberheide and 2 more

Abstract readComparative Study
In one paragraph

Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Manon ThierryDepartment of Neurology, Center for Cognitive Neurology, Grossman School of Medicine, New York University, Science Building, Rm 1017, 435 East 30th Street, New York, NY, 10016, USA. manon.thierry@icm-institute.org.
Dominique LeitnerDepartment of Neurology, Center for Cognitive Neurology, Grossman School of Medicine, New York University, Science Building, Rm 1017, 435 East 30th Street, New York, NY, 10016, USA.
Kaleah BalcombBrain and Mind Centre and School of Medical Science, University of Sydney, Camperdown, NSW, 2050, Australia.
Tomas KavanaghBrain and Mind Centre and School of Medical Science, University of Sydney, Camperdown, NSW, 2050, Australia.
Lauren TangDepartment of Biochemistry and Molecular Pharmacology, Proteomics Laboratory, Grossman School of Medicine, New York University, New York, NY, 10016, USA.
Evgeny KanshinDepartment of Biochemistry and Molecular Pharmacology, Proteomics Laboratory, Grossman School of Medicine, New York University, New York, NY, 10016, USA.
Christopher WilliamDepartment of Pathology, Grossman School of Medicine, New York University, New York, NY, 10016, USA.
Derek OakleyDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Bradley HymanDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Beatrix UeberheideDepartment of Neurology, Center for Cognitive Neurology, Grossman School of Medicine, New York University, Science Building, Rm 1017, 435 East 30th Street, New York, NY, 10016, USA.
Eleanor DrummondBrain and Mind Centre and School of Medical Science, University of Sydney, Camperdown, NSW, 2050, Australia.
Thomas WisniewskiDepartment of Neurology, Center for Cognitive Neurology, Grossman School of Medicine, New York University, Science Building, Rm 1017, 435 East 30th Street, New York, NY, 10016, USA. thomas.wisniewski@nyulangone.org.ORCID https://orcid.org/0000-0002-3379-8966

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Research Education ComponentP30AG066512 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Mary Sherman Mittelman · 2020 to 2026
$28.4M
ARIA Pathophysiology Characterized by in vivo Neuroimaging, Plasma Biomarkers and Post-Mortem ProteomicsU24NS141774 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GE, YULIN, LU, HANZHANG · 2025 to 2025
$3.3M
NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG066512NIH HHS P30AG062421NIH HHS P30AG066512 and U24NS141774NINDS NIH HHS U24 NS141774
6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterised by the intraneuronal aggregation of phosphorylated Tau (pTau) into neurofibrillary tangles and by the extracellular deposition of β-amyloid (Aβ). Tau pathology restricted to the hippocampal formation is frequently observed in the elderly brain in the absence of any Aβ deposition and considered as "primary age-related tauopathy" (PART). Here, we applied an unbiased proteomic approach to determine how concomitant Aβ pathology modifies the neurofibrillary tangle proteome. Neurofibrillary tangles were isolated by dissecting Tau pSer202/pThr205 "AT8" immunopositive neuronal profiles, combining chromogenic immunohistochemistry with laser capture microdissection, from hippocampal sections of 17 post-mortem brains spanning three groups: PART (n = 5; A0, B1-2, C0 scores), intermediate AD (n = 6; A1-2, B2-3, C1-2 scores) and advanced AD (n = 6; A3, B3, C3 scores). A label-free quantitative liquid chromatography-mass spectrometry based proteomic analysis, using data independent acquisition (DIA) on a Bruker timsTOF, was performed. A conserved core of 63 proteins was identified as enriched in tangles across all groups, mostly associated with "RNA binding" and "regulation of mRNA metabolic process", based on the Gene Ontology database. Group-specific signatures were also observed: 33 proteins were significantly enriched only in tangles collected from PART cases and were predominantly linked to "structural molecule activity", whereas Aβ-positive cases showed specific enrichment of "RNA binding" and "cytoplasmic translation" pathways-with intermediate AD cases displaying a transitional profile. Our findings are consistent with PART having distinct tangle proteomic features; however, the majority of its proteomic signature is in common with tangles within the AD continuum. By addressing how Aβ accumulation alters the tangle proteome, this study provides mechanistic insights into the expansion of Tau pathology, paving the way towards the identification of biomarkers and therapeutic strategies that would allow for stabilisation of Tau pathology in the elderly.

Indexed as

Alzheimer DiseaseHippocampusNeurofibrillary TanglesAgedAged, 80 and overAmyloid beta-PeptidesFemaleHumansLaser Capture MicrodissectionMaleProteomicstau ProteinsAmyloid beta-Peptidestau ProteinsAlzheimerAβNeurofibrillary tanglesPARTProteomicsTau

Identifiers

PMID42542447
PMCPMC13428778

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.